The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 6 undervalued stocks in the Pharmaceuticals industry for Tuesday, May 13, 2025. Let’s take ...

Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD-1/L1 therapySEED's first-in-class RBM39 degrader, reported ...

Cells have a trick called splicing. They can cut a gene's message into pieces and decide which fragments to keep. By mixing ...

New research by scientists at the University of Toronto and the Structural Genomics Consortium has deepened our understanding ...

Senior congressional correspondent Chad Pergram provides details on the fallout from Democrats' demonstration at an ICE ...

Metastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge, with low 5-year survival rates and limited durable responses to existing therapies. While standard ...

Accumulating evidence suggests that the immune system plays a crucial role in the emergence of atherosclerotic cardiovascular ...

Researchers confirm and explore the role of estrogen-related receptors in regulating energy production in muscle cells during exercise. The findings indicate that developing a drug to boost ...

R&D expense for the first quarter of 2025 was $7.8 million, compared to $7.6 million for the first quarter of 2024. The increase of $0.2 million was primarily due to clinical trial expenses associated ...